Protein engineering at Antibody Engineering 2026

Dec 13–16, 2026 San Diego, CA ~900 attendees Website

39 organizations at Antibody Engineering 2026 present work in protein engineering: 17 drug developers, 13 suppliers and service providers and 9 academic, government and non-profit bodies. Between them they bring 56 presentations to the program. Most represented: Xencor (4 on the program), Amgen (3 on the program), Genentech (3 on the program). As of Nov 10, 2026.

All 168 organizations at Antibody Engineering 2026 →

Format
Top represented
Showing 1–12 of 39 organizations
OrganizationAntibody Engineering 2026 Attendance
Xencor
Pasadena, CA
Biotech
Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases.
Chair
Sun Dec 13
1:00pm–1:15pm
Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen
Talk
Sun Dec 13
4:15pm–5:00pm
Moderated Panel Discussion with Session Speakers
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen
Chair
Mon Dec 14
8:00am–8:05am
Co-Chairs' Welcome and Opening Remarks
Keynote Presentations - Livestream · with Gyes
Talk
Mon Dec 14
10:55am–11:30am
Jim Huston Science Talent Award and Presentation
Keynote Presentations - Livestream · with Dana-Farber Cancer Institute, Johnson & Johnson
Chair
Wed Dec 16
8:10am–8:15am
Co-Chairs’ Remarks
Track 2: Engineering Antibody Interfaces: Unlocking New Biology · with Dualitas Therapeutics
Talk
Wed Dec 16
9:15am–9:45am
XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life
Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood.
Bispecifics & multispecifics
Amgen
Thousand Oaks, CA
Large pharma
Global biopharmaceutical company developing and manufacturing biologic medicines, including bispecific T-cell engagers.
Chair
Sun Dec 13
1:00pm–1:15pm
Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor
Talk
Sun Dec 13
1:15pm–1:45pm
Developability-Guided Generative Biology for Therapeutic Protein Engineering
Designing new therapeutic proteins by computer while checking from the start that they can be made and purified.
AI & computational design
Talk
Sun Dec 13
4:15pm–5:00pm
Moderated Panel Discussion with Session Speakers
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor
Talk
Mon Dec 14
5:45pm–6:15pm
Induced Proximity and Next-Generation Antibody Therapeutics
Track 2: Engineering Solutions for Accessing Difficult Targets
Bispecifics & multispecifics
Genentech
South San Francisco, CA
Large pharma
Biotechnology company and Roche Group member that discovers, develops and markets antibody and other medicines.
Talk
Sun Dec 13
11:00am–11:45am
Career Path/Experiences Panel Discussion
Early Career Scientist Session · with Macaw Therapeutics, AstraZeneca, Adaxion Therapeutics
Talk
Mon Dec 14
2:30pm–3:00pm
Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders
How the shape of antibody binding decides whether a target protein on the cell surface is actually destroyed.
Bispecifics & multispecifics
Chair
Tue Dec 15
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Advanced In Vivo Approaches to Antibody Discovery · with Johnson & Johnson
Talk
Tue Dec 15
8:15am–8:45am
From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins
Immunizing animals with mRNA packaged in tiny fat particles, so their antibodies recognize proteins embedded in cell membranes.
Protein engineering
Regeneron
Tarrytown, NY
Large pharma
Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform.
Talk
Sun Dec 13
3:45pm–4:15pm
From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics
How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule.
Talk
Mon Dec 14
5:15pm–5:45pm
Targeting IgE Responses
Track 2: Engineering Solutions for Accessing Difficult Targets
Beyond oncology
Chair
Wed Dec 16
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Rondo Therapeutics
University of Southampton
Southampton, United Kingdom
Academic
Public research university whose Centre for Cancer Immunology works on antibody immunotherapy and Fc receptor biology.
Chair
Mon Dec 14
2:25pm–2:30pm
Co-Chairs’ Remarks
Track 2: Engineering Solutions for Accessing Difficult Targets · with Macaw Therapeutics
Talk
Mon Dec 14
4:45pm–5:15pm
Disulfide Engineering of Immunostimulatory Antibodies for Augmented Receptor Agonism and Immune Cell Stimulation
Adding chemical bridges between an antibody's two arms to lock its shape and make it switch on immune cells more strongly.
Protein engineering
Chair
Tue Dec 15
8:10am–8:15am
Co-Chairs' Remarks
Track 2: Antibody Engineering for Proximity-Based Approaches · with Chai Discovery
Large pharma
Japanese pharmaceutical company and Roche Group member known for antibody engineering technologies such as recycling and bispecific antibodies.
Talk
Mon Dec 14
3:30pm–4:00pm
Protease-Activated IL-12 Masking via Engineered VH Dissociation and IL-12 Intrinsic activity Enables Tunable Cytokine Activation
Caging a powerful immune-signaling protein so it only switches on where tumor enzymes cut the cage open.
Talk
Tue Dec 15
4:45pm–5:15pm
Long Acting Anti-latent TGF-β1 Recycling Antibody for Fibrotic Diseases
An antibody that is recycled back out of cells, letting it block a scarring-driving growth factor for far longer.
Protein engineering
City of Hope
Duarte, CA
Academic
Cancer research and treatment center with a graduate school.
Talk
Wed Dec 16
4:15pm–4:45pm
MPACT: Engineering the Fc–FcγR Interface for Plug-and-Play, Mixed-Valency Multispecific Antibodies
Using a chemical bond at a natural antibody contact point to snap extra targeting or immune-activating parts onto one antibody.
Bispecifics & multispecifics
Talk
Wed Dec 16
4:15pm–4:45pm
Turning up the Heat: Radioimmunoconjugates for Targeted Radiation Therapy
Using antibodies and smaller antibody pieces to carry radioactive atoms that both image and irradiate tumors.
Genmab
Copenhagen, Denmark
Biotech
Danish antibody company with marketed cancer medicines, developing bispecific antibodies and antibody-drug conjugates.
Chair
Tue Dec 15
2:25pm–2:30pm
Co-Chairs' Remarks
Track 2: Expanding Therapeutic Applications: Utility of Antibodies Beyond Oncology · with Lust for Life Science
Talk
Wed Dec 16
11:30am–12:00pm
Enabling Polyclonal Antibody Production through Fc-engineering of Mutual Exclusive CH3 Interfaces
Reshaping the region where two antibody halves join, so several different antibodies can be made together in one mixture without mismatching.
Gyes
Naarden, Netherlands
Biotech
Dutch biotech building multispecific antibodies that act only on cells co-expressing target combinations, for cancer and immune diseases.
Chair
Mon Dec 14
8:00am–8:05am
Co-Chairs' Welcome and Opening Remarks
Keynote Presentations - Livestream · with Xencor
Chair
Wed Dec 16
2:10pm–2:15pm
Chairs’ Remarks
Track 2: Engineering Innovative Functionality into Antibody Domains
Harvard University
Cambridge, MA
Academic
Private research university, including Harvard Medical School.
Talk
Mon Dec 14
2:30pm–3:00pm
Discovery of G protein-coupled Receptor Modulator Antibody Fragments
Small antibody fragments that switch on or block the large family of signal-receiving proteins in cell membranes.
Protein engineering
Talk
Wed Dec 16
8:15am–8:45am
A New Homotypic Interface Expands Anti-Malarial Antibody Recognition Breadth
Evolving a malaria antibody so copies of it grip each other in a new way and protect against more parasite strains.
Beyond oncology
Biotech
Immunology company developing antibody-based medicines for autoimmune diseases, with marketed FcRn-blocking therapy.
Talk
Wed Dec 16
4:45pm–5:15pm
A Novel Antibody Approach to Pan-subclass IgG Reduction
An antibody that sweeps up and destroys every subtype of the main antibody class in blood, for diseases caused by self-attacking antibodies.
Beyond oncology
Biotech
Biotech with no public profile yet; on this program it co-chairs the track on engineering antibodies for difficult targets.
Talk
Sun Dec 13
11:00am–11:45am
Career Path/Experiences Panel Discussion
Early Career Scientist Session · with AstraZeneca, Genentech, Adaxion Therapeutics
Chair
Mon Dec 14
2:25pm–2:30pm
Co-Chairs’ Remarks
Track 2: Engineering Solutions for Accessing Difficult Targets · with University of Southampton

Explore the full Antibody Engineering 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Diego. Leave your work email and we’ll be in touch.

Privacy

Download the full Antibody Engineering 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in protein engineering

Tell us what you sell and we’ll find the people at organizations working on protein engineering most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse Antibody Engineering 2026 by

Exhibit hall

Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction